Premium
Marked reduction in haemoglobin levels secondary to ceftizoxime‐induced immune haemolytic anaemia in diabetic patients
Author(s) -
Wu Shengjie,
Jing Li,
Feng Yipeng,
Chen Liping
Publication year - 2020
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.13135
Subject(s) - ceftizoxime , immune system , medicine , immunology , biology , microbiology and biotechnology , antibiotics , cephalosporin
What is known and objective Drug‐induced immune haemolytic anaemia (DIIHA) is rare and difficult to diagnose. In diabetic patients, the diagnosis of DIIHA is even harder. In the current study, we report on two cases of ceftizoxime‐induced immune haemolytic anaemia in diabetic patients. Case description Two diabetic patients (suffering from type 1 and type 2 diabetes mellitus, respectively) presented with rapid reduction in haemoglobin levels when exposed to ceftizoxime (2g q12h). They both achieved symptom improvement after switching to another antibiotic. What is new and conclusion The persistently reduced haemoglobin levels in diabetic patients may contribute to DIIHA. Reviewing patients' medical records might provide some valuable clues as to the causes of DIIHA.